NCT03668405 is a Phase 1 clinical trial of Lu AF20513 in Alzheimer's Disease, sponsored by H. Lundbeck A/S.

Who is sponsoring NCT03668405?

NCT03668405 is sponsored by H. Lundbeck A/S.

What drugs are being tested in NCT03668405?

Interventions in NCT03668405: Lu AF20513.

What condition does NCT03668405 study?

NCT03668405 studies Alzheimer's Disease.

Is NCT03668405 still recruiting?

NCT03668405 is currently terminated. Last updated 21 November 2019.

Last reviewed 2019-11-21 · How we verify

NCT03668405

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Long-term Safety and Tolerability of Lu AF20513 and the Antibody Response in Patients With Alzheimer's Disease (AD)

Terminated Phase 1 Last updated 21 November 2019

What this trial tests

Phase 1 trial testing Lu AF20513 in Alzheimer's Disease in 18 participants. Terminated before completion.

Timeline

26 June 2018

Primary endpoint
27 May 2019

27 May 2019

Quick facts

Lead sponsor	H. Lundbeck A/S
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	26 June 2018
Primary completion	27 May 2019
Estimated completion	27 May 2019
Sites	4 locations across Sweden, Finland

Drugs / interventions tested

Lu AF20513 — full drug profile →

Conditions studied

Alzheimer's Disease — all drugs for Alzheimer's Disease →

Sponsor

H. Lundbeck A/S — full company profile →

Who can join

Adults 60 to 85, any sex, with Alzheimer's Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the long-term safety, tolerability and antibody response of Lu AF20513 in patients with Alzheimer's disease who have completed the 16026A study.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Alzheimer's disease drug development pipeline: 2019.
Cummings J, Lee G, Ritter A, Sabbagh M, et al · · 2019 · cited 485× · PMID 31334330 · DOI 10.1016/j.trci.2019.05.008
Detection and treatment of Alzheimer's disease in its preclinical stage.
Rafii MS, Aisen PS. · · 2023 · cited 104× · PMID 37202518 · DOI 10.1038/s43587-023-00410-4
Roles and Mechanisms of the Protein Quality Control System in Alzheimer's Disease.
Liu Y, Ding R, Xu Z, Xue Y, et al · · 2021 · cited 16× · PMID 35008771 · DOI 10.3390/ijms23010345
Biologics as Therapeutical Agents Under Perspective Clinical Studies for Alzheimer's Disease.
Li H, Shen X, Zhang B, Zhu Z. · · 2025 · cited 7× · PMID 40942007 · DOI 10.3390/molecules30173479
Neuro-Immune Crosstalk: Molecular Mechanisms, Biological Functions, Diseases, and Therapeutic Targets.
Guo X, Liu H, Song YJ, Wang JH, et al · · 2026 · cited 2× · PMID 41583906 · DOI 10.1002/mco2.70497

Verify or expand the search:

Other trials of Lu AF20513

Trials testing the same drug.

NCT03819699 — Study With Lu AF20513 in Patients With Mild Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI) Due to AD · Phase 1 · terminated

Other recruiting trials for Alzheimer's Disease

Currently open trials in the same condition.

NCT07457138 — Lombard Cohort of Brain Health Services · recruiting
NCT07234942 — A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants Wit · Phase 1 · recruiting
NCT07479914 — Art of Memory for Cognitive Enhancement in the Monza Brain Health Service · NA · active not recruiting
NCT07214727 — A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease · Phase 1 · recruiting
NCT07105709 — Open-label Extension Study in Participants With Early Alzheimer's Disease · Phase 2 · recruiting

Other H. Lundbeck A/S trials

Trials by the same sponsor.

NCT07514858 — A Trial Investigating Lu AF28996 in Adults With Parkinson's Disease Who Have Motor Fluctuations · Phase 2 · not yet recruiting
NCT07513441 — A Trial of Lu AF28996 in Participants With Parkinson's Disease (PD) · Phase 1 · not yet recruiting
NCT06701526 — A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications · Phase 4 · active not recruiting
NCT06706622 — A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) · Phase 3 · active not recruiting
NCT06557850 — A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease · Phase 1 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03668405 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by H. Lundbeck A/S
Last refreshed: 21 November 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03668405.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing